Hyponatremia and Cancer: From Bedside to Benchside

Area of Science:

• Oncology
• Endocrinology
• Nephrology

Background:

• Hyponatremia is a frequent electrolyte disorder in hospitalized patients, particularly those with cancer.
• The syndrome of inappropriate antidiuresis, often due to ectopic arginine vasopressin secretion by tumors or chemotherapy, is a primary cause in cancer patients.
• Hyponatremia is linked to poorer prognoses in various diseases, including cancer, negatively impacting progression-free and overall survival.

Purpose of the Study:

• To explore the role of hyponatremia in cancer patient outcomes.
• To investigate the potential of vasopressin receptor antagonists (vaptans) as an anti-cancer therapeutic strategy.

Main Methods:

• Review of existing literature on hyponatremia in cancer.
• Analysis of in vitro studies examining the effects of low sodium and vaptans on cancer cell behavior.
• Examination of clinical data correlating hyponatremia correction with patient outcomes.

Main Results:

• Hyponatremia negatively affects survival in multiple cancer types.
• Low extracellular sodium concentrations in vitro enhance cancer cell proliferation and motility.
• Vasopressin receptor antagonists demonstrate in vitro antiproliferative and anti-invasive effects on cancer cells.

Conclusions:

• Correction of serum sodium levels may improve cancer patient outcomes.
• Vasopressin receptor antagonists exhibit potential as a novel pharmacological approach to counteract cancer cell proliferation and invasivity.
• Further research into vaptans for cancer treatment is warranted.